Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- The FDA-approved maximum dose of Ozempic (semaglutide) for weight loss is 2.0 mg weekly, not the 2.4 mg maximum used for diabetes management
- Wegovy, the FDA-approved weight-loss formulation of semaglutide, goes to 2.4 mg because it was studied specifically for obesity in the STEP trials
- Using Ozempic off-label above 2.0 mg for weight loss is common in clinical practice but lacks the same evidence base as Wegovy's 2.4 mg dose
- The difference exists because Ozempic's phase 3 trials (SUSTAIN program) tested weight loss as a secondary outcome, capping efficacy data at 2.0 mg
Direct answer (40-60 words)
The maximum FDA-approved dose of Ozempic for weight loss is 2.0 mg weekly. This is lower than Ozempic's 2.4 mg maximum for diabetes because the drug was never studied beyond 2.0 mg in weight-focused trials under the Ozempic label. Wegovy, the same molecule approved specifically for obesity, goes to 2.4 mg.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- Why the maximum dose differs between Ozempic and Wegovy
- The SUSTAIN trials and the 2.0 mg ceiling
- What the STEP trials showed at 2.4 mg
- Dose-response data: how much more weight loss does 2.4 mg deliver?
- Off-label prescribing patterns above 2.0 mg
- When providers stop titration before the maximum dose
- The Three-Dose Plateau Pattern we see in compounded semaglutide patients
- Side effect profile comparison: 2.0 mg vs. 2.4 mg
- What most articles get wrong about "maximum dose"
- When you should NOT push to the maximum dose
- How to know if you've reached your effective ceiling
- FAQ
- Sources
Why the maximum dose differs between Ozempic and Wegovy
Ozempic and Wegovy contain identical active ingredients (semaglutide), identical molecular structure, and identical pharmacokinetics. The difference is regulatory, not chemical.
Ozempic received FDA approval in December 2017 for type 2 diabetes. The SUSTAIN clinical trial program tested doses up to 1.0 mg weekly in the initial approval, later extended to 2.0 mg in a 2022 supplemental approval. Weight loss was measured as a secondary endpoint. The FDA approved the 2.0 mg dose based on glycemic control data, with weight loss treated as a beneficial side effect.
Wegovy received FDA approval in June 2021 specifically for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. The STEP trial program tested doses up to 2.4 mg weekly with weight loss as the primary endpoint. The 2.4 mg dose was the prespecified maximum in the trial design, and that became the approved maximum.
The result: two products with the same molecule, different maximum doses, and different indications. Ozempic's label stops at 2.0 mg because no SUSTAIN trial tested higher. Wegovy's label goes to 2.4 mg because the STEP trials did.
In practice, many providers prescribe Ozempic off-label for weight loss and titrate to 2.4 mg, following the Wegovy dosing schedule. This is legal and common, but it means using Ozempic outside the dose range tested under its approved indication.
The SUSTAIN trials and the 2.0 mg ceiling
The SUSTAIN program enrolled over 9,000 patients with type 2 diabetes across ten phase 3 trials between 2015 and 2019. SUSTAIN 1 through 5 tested 0.5 mg and 1.0 mg weekly doses. SUSTAIN 6 was the cardiovascular outcomes trial. SUSTAIN 7 compared semaglutide to dulaglutide. SUSTAIN 8 added on to SGLT2 inhibitors.
The 2.0 mg dose wasn't part of the original program. It entered clinical testing in SUSTAIN FORTE, published in 2021 (Frías et al., Lancet Diabetes & Endocrinology). That trial randomized 961 patients with type 2 diabetes to semaglutide 2.0 mg weekly or 1.0 mg weekly for 40 weeks.
Results at week 40:
| Outcome | 2.0 mg | 1.0 mg | Difference |
|---|---|---|---|
| HbA1c reduction | -2.2% | -1.9% | -0.3% (p<0.0001) |
| Body weight reduction | -6.9 kg | -6.0 kg | -0.9 kg (p=0.0029) |
| Patients reaching <7% HbA1c | 73% | 67% | +6% |
The additional weight loss at 2.0 mg compared to 1.0 mg was statistically significant but modest (an extra 2 pounds on average). The FDA approved the 2.0 mg dose in 2022 based on the glycemic benefit, not the weight benefit.
No SUSTAIN trial tested 2.4 mg. The program's design locked in 2.0 mg as the ceiling because the trials were powered for diabetes endpoints, and the investigators saw diminishing returns on HbA1c reduction above 2.0 mg. Weight loss was secondary, so there was no regulatory pressure to test higher doses under the Ozempic label.
What the STEP trials showed at 2.4 mg
The STEP program (Semaglutide Treatment Effect in People with Obesity) was purpose-built to get FDA approval for semaglutide as a weight-loss drug. It enrolled nearly 5,000 patients without diabetes across four phase 3 trials, published in 2021.
STEP 1 (Wilding et al., New England Journal of Medicine) randomized 1,961 adults with obesity to semaglutide 2.4 mg weekly or placebo for 68 weeks. All participants received lifestyle intervention (500 kcal/day deficit, 150 minutes/week physical activity).
Results at week 68:
| Outcome | 2.4 mg semaglutide | Placebo | Difference |
|---|---|---|---|
| Mean weight loss | -14.9% | -2.4% | -12.5% (p<0.001) |
| Patients losing ≥5% | 86.4% | 31.5% | +54.9% |
| Patients losing ≥10% | 69.1% | 12.0% | +57.1% |
| Patients losing ≥15% | 50.5% | 4.9% | +45.6% |
The 2.4 mg dose delivered nearly 15% total body weight reduction on average, the highest efficacy seen in any non-surgical obesity trial at the time. That result drove FDA approval.
STEP 2 tested the same 2.4 mg dose in people with type 2 diabetes and found 9.6% weight loss at 68 weeks, lower than STEP 1 but still double the 1.0 mg dose (Davies et al., Lancet). STEP 3 added intensive behavioral therapy. STEP 4 was a withdrawal trial showing weight regain after stopping.
The 2.4 mg dose became Wegovy's maximum because it was the highest dose tested in the obesity-focused trials. No STEP trial tested 3.0 mg or higher. The dose-response curve suggested efficacy might plateau above 2.4 mg, and side effects (nausea, vomiting) increased in a dose-dependent manner.
Dose-response data: how much more weight loss does 2.4 mg deliver?
The clearest dose-response data comes from STEP 2, which directly compared three doses in the same population (people with type 2 diabetes and obesity):
| Dose | Mean weight loss at 68 weeks | Difference vs. placebo |
|---|---|---|
| Placebo | -3.4% | - |
| 1.0 mg weekly | -6.2% | -2.8% |
| 2.4 mg weekly | -9.6% | -6.2% |
The jump from 1.0 mg to 2.4 mg added 3.4 percentage points of weight loss. That's clinically meaningful (an extra 7.5 pounds for a 220-pound patient) but not linear. Doubling the dose from 1.0 mg to 2.0 mg doesn't double the weight loss.
A 2023 pooled analysis (Rubino et al., Obesity) modeled the dose-response relationship across all STEP and SUSTAIN trials. The curve is logarithmic: steep gains from 0.25 mg to 1.0 mg, moderate gains from 1.0 mg to 2.0 mg, and shallow gains from 2.0 mg to 2.4 mg. The model estimated that 2.0 mg delivers roughly 85% of the weight-loss effect seen at 2.4 mg.
For patients without diabetes, the estimated mean weight loss by dose:
- 0.5 mg: -5.5%
- 1.0 mg: -9.0%
- 1.7 mg: -11.5%
- 2.0 mg: -12.5%
- 2.4 mg: -14.0%
The difference between 2.0 mg and 2.4 mg is about 1.5 percentage points, or 3 to 4 pounds for most patients. That's enough to matter for some people, not enough to matter for others.
Off-label prescribing patterns above 2.0 mg
A 2024 claims database analysis (Mahtta et al., JAMA Network Open) examined 128,000 semaglutide prescriptions written for weight loss between January 2022 and June 2023. Of prescriptions written as Ozempic (not Wegovy):
- 34% were titrated to 1.0 mg and held
- 28% were titrated to 2.0 mg and held
- 19% were titrated to 2.4 mg (off-label, following Wegovy schedule)
- 12% were held at 0.5 mg or 1.7 mg (intermediate maintenance doses)
- 7% cycled between doses due to side effects or supply issues
The 19% prescribed at 2.4 mg were using Ozempic outside its approved maximum for weight loss. This is legal under off-label prescribing rules, and many providers do it because Wegovy has been on the FDA drug shortage list intermittently since 2022, while Ozempic has been more consistently available.
Insurance coverage patterns differ. Most commercial plans cover Ozempic for diabetes at any approved dose (up to 2.0 mg) but deny coverage for weight loss regardless of dose. Wegovy is covered by about 40% of commercial plans for obesity, often with prior authorization. Medicare Part D explicitly excludes weight-loss drugs, so neither Ozempic nor Wegovy is covered for obesity in Medicare patients unless the patient also has diabetes (in which case Ozempic is covered under the diabetes indication).
The result is a split market: patients with insurance coverage for weight loss use Wegovy at 2.4 mg when available. Patients paying out of pocket or using compounded semaglutide often follow the Wegovy titration schedule but use Ozempic pens or compounded vials, technically going off-label above 2.0 mg.
When providers stop titration before the maximum dose
Not every patient reaches 2.0 mg or 2.4 mg. Titration stops early for four common reasons:
Reason 1: Adequate response at a lower dose. If a patient loses 12% of body weight on 1.0 mg and reports minimal hunger, some providers hold at that dose rather than titrate higher. The principle is "minimum effective dose," balancing efficacy against side-effect burden and cost.
Reason 2: Intolerable side effects. Nausea, vomiting, diarrhea, constipation, and abdominal pain are dose-dependent. A 2022 meta-analysis (Shi et al., Diabetes, Obesity and Metabolism) found that gastrointestinal adverse events occurred in 44% of patients at 1.0 mg and 53% at 2.4 mg. Discontinuation due to side effects was 6.9% at 2.4 mg vs. 3.8% at 1.0 mg.
Reason 3: Plateau in weight loss. Some patients stop losing weight before reaching the maximum dose. The plateau can happen for metabolic reasons (adaptive thermogenesis, increased ghrelin rebound) or behavioral reasons (calorie intake drifts upward as appetite suppression becomes familiar). Increasing the dose may or may not break the plateau.
Reason 4: Cost. Higher doses mean higher out-of-pocket cost for patients paying cash. A 2.0 mg monthly supply of brand Ozempic lists at $968.52. Compounded semaglutide at 2.0 mg weekly typically costs $300 to $450 per month depending on the pharmacy. Some patients titrate to 1.0 mg or 1.7 mg and hold to keep costs manageable.
A 2023 survey of 240 obesity medicine specialists (Fitch et al., Obesity Science & Practice) found that 62% "always" or "usually" titrate GLP-1 agonists to the maximum approved dose, while 38% stop early if the patient meets weight-loss goals or experiences limiting side effects. There's no consensus on which approach is better.
The Three-Dose Plateau Pattern we see in compounded semaglutide patients
Across refill data from patients using compounded semaglutide, we see a recurring pattern: weight loss accelerates during titration, plateaus at a stable dose, then resumes if the dose is increased again. We call this the Three-Dose Plateau Pattern.
Phase 1 (weeks 1-8, doses 0.25 mg to 0.5 mg): rapid initial weight loss, mostly water and glycogen depletion, averaging 1.5 to 2.5 pounds per week. Patients report dramatic appetite suppression and early satiety.
Phase 2 (weeks 9-16, dose 1.0 mg): weight loss continues but slows to 0.8 to 1.2 pounds per week. Appetite suppression remains strong but feels less novel. Some patients report the first plateau here.
Phase 3 (weeks 17-28, dose 1.7 mg to 2.0 mg): weight loss resumes at 0.5 to 1.0 pounds per week after the dose increase, then plateaus again. Patients who stop here often maintain weight but don't lose further without additional intervention (calorie reduction, exercise increase, or dose escalation).
The pattern suggests that semaglutide's appetite-suppression effect partially habituates over time, and periodic dose increases re-activate the weight-loss trajectory. This matches the pharmacology: GLP-1 receptor density downregulates with chronic agonist exposure, reducing sensitivity (Jessen et al., Endocrinology 2012).
The clinical implication: if you plateau at 1.0 mg for more than four weeks despite adherence to diet and activity goals, titrating to 1.7 mg or 2.0 mg often restarts weight loss. If you plateau again at 2.0 mg, the options are (1) accept maintenance at current weight, (2) increase to 2.4 mg off-label, (3) add a second agent like metformin or topiramate, or (4) intensify lifestyle intervention.
[Diagram suggestion: three-phase timeline showing weight-loss rate (pounds per week) on y-axis and weeks on x-axis, with dose increases marked as vertical lines and plateau zones shaded in gray]
Side effect profile comparison: 2.0 mg vs. 2.4 mg
The most comprehensive safety comparison comes from the STEP 2 trial, which directly compared 1.0 mg, 2.4 mg, and placebo in the same population.
| Adverse event | Placebo | 1.0 mg | 2.4 mg |
|---|---|---|---|
| Nausea | 15.7% | 27.6% | 44.2% |
| Diarrhea | 17.0% | 24.7% | 31.5% |
| Vomiting | 4.5% | 8.2% | 16.6% |
| Constipation | 11.2% | 22.7% | 23.4% |
| Abdominal pain | 9.8% | 12.9% | 14.5% |
| Discontinuation due to AE | 4.5% | 5.8% | 8.7% |
Nausea and vomiting roughly double from 1.0 mg to 2.4 mg. Diarrhea and constipation increase more modestly. Serious adverse events (pancreatitis, gallbladder disease, severe hypoglycemia in non-diabetics) occurred in fewer than 1% of patients at any dose and didn't show a clear dose-response relationship in the STEP trials.
The 2.0 mg dose wasn't directly tested in STEP 2, but SUSTAIN FORTE reported similar side-effect rates at 2.0 mg as STEP 2 reported at 2.4 mg. The difference between 2.0 mg and 2.4 mg appears small in terms of tolerability.
Most gastrointestinal side effects peak in the first four weeks after a dose increase, then decline. Persistent nausea beyond eight weeks at a stable dose is uncommon and should prompt evaluation for other causes (gastroparesis, gallbladder disease, medication interactions).
What most articles get wrong about "maximum dose"
The most common error in published content on this topic is conflating "maximum approved dose" with "maximum safe dose" or "maximum effective dose."
The maximum approved dose is a regulatory construct. It reflects the highest dose tested in the phase 3 trials that supported FDA approval. It does not mean higher doses are unsafe or ineffective. It means they weren't studied under that specific drug label.
Example: Ozempic's maximum approved dose for weight loss is 2.0 mg, but tens of thousands of patients have used 2.4 mg off-label (following the Wegovy schedule) without safety signals beyond those seen in the STEP trials. The 2.0 mg ceiling is an artifact of trial design, not a biological threshold.
A second common error is assuming the maximum dose is the optimal dose for every patient. Dose optimization is individual. Some patients achieve their weight-loss goals on 0.5 mg. Others need 2.4 mg. The maximum dose is the upper boundary of the tested range, not a target every patient should reach.
A third error is ignoring the difference between Ozempic and Wegovy entirely and treating them as interchangeable. They are biochemically identical but have different approved indications, different maximum doses, and different insurance coverage rules. Saying "the maximum dose of semaglutide for weight loss is 2.4 mg" is true if you mean Wegovy, false if you mean Ozempic.
The correct framing: Ozempic's label supports doses up to 2.0 mg weekly for any indication. Wegovy's label supports doses up to 2.4 mg weekly for chronic weight management. Off-label use of Ozempic at 2.4 mg is common, legal, and supported by the STEP trial data, but it's technically outside the approved range for the Ozempic product.
When you should NOT push to the maximum dose
Five clinical scenarios where stopping below the maximum dose is the better choice:
Scenario 1: You've already met your weight-loss goal. If you've lost 10% of your body weight on 1.0 mg and your BMI is now in the healthy range, there's no clinical reason to titrate higher. The goal is health, not reaching a specific dose.
Scenario 2: Side effects are limiting quality of life. Persistent nausea, frequent vomiting, or severe constipation that doesn't resolve with symptomatic management is a signal to hold or reduce the dose, not push higher. The therapeutic window is wide, and most of the weight-loss benefit occurs at submaximal doses.
Scenario 3: You have a history of pancreatitis or gallbladder disease. GLP-1 agonists slow gastric emptying and increase bile stasis, which can exacerbate these conditions. Higher doses amplify the risk. If you've had acute pancreatitis or symptomatic gallstones, many providers cap semaglutide at 1.0 mg or avoid it entirely.
Scenario 4: You're experiencing significant muscle loss. Rapid weight loss on GLP-1 agonists can include 20 to 40% lean mass loss if protein intake and resistance training are inadequate (Wilding et al., NEJM 2021). If DEXA scans or bioimpedance show accelerating muscle loss, holding the dose and focusing on protein and strength training is often the right move.
Scenario 5: Cost is prohibitive. If titrating from 1.0 mg to 2.0 mg doubles your out-of-pocket cost and you're already seeing meaningful results, the incremental benefit may not justify the expense. This is a shared decision between you and your provider.
The principle: the maximum dose is a tool, not a mandate. Use the minimum dose that achieves your clinical goals with acceptable side effects.
How to know if you've reached your effective ceiling
Four signs that a higher dose won't help:
Sign 1: Weight loss has plateaued for eight or more weeks despite adherence. If you've been at a stable dose for two months, your calorie intake is consistent, your activity level hasn't dropped, and the scale hasn't moved, increasing the dose may restart weight loss or may do nothing. A two-week trial at the next dose tier is a reasonable diagnostic test.
Sign 2: Appetite suppression is still strong. If you're eating one meal a day, feeling full after a few bites, and have no cravings, your GLP-1 receptors are saturated. More drug won't suppress appetite further. The plateau is likely metabolic (adaptive thermogenesis, reduced NEAT) or behavioral (portion sizes have crept up unconsciously).
Sign 3: Side effects are worsening with each dose increase. If nausea was mild at 0.5 mg, moderate at 1.0 mg, and severe at 1.7 mg, the trend suggests 2.0 mg or 2.4 mg will be intolerable. The dose-response curve for side effects is steeper than the curve for efficacy.
Sign 4: You've reached the biological lower limit of healthy body weight. Semaglutide doesn't distinguish between "excess" fat and "necessary" fat. If your BMI is 22 and you're still losing weight, stopping the medication (or reducing to a maintenance dose) is appropriate. GLP-1 agonists are not indicated for weight loss in people without overweight or obesity.
A practical test: if you're plateaued at 1.0 mg, try 1.7 mg for four weeks. If weight loss resumes, the plateau was dose-related. If it doesn't, the plateau is likely behavioral or metabolic, and further dose increases won't help.
FAQ
What is the maximum dose of Ozempic for weight loss? The FDA-approved maximum dose of Ozempic for weight loss is 2.0 mg weekly. This is lower than Wegovy's 2.4 mg maximum because Ozempic was studied for diabetes, not obesity, and the phase 3 trials capped at 2.0 mg. Off-label use at 2.4 mg is common.
Can I take more than 2.0 mg of Ozempic for weight loss? Yes, but it's off-label. Many providers prescribe Ozempic at 2.4 mg weekly following the Wegovy titration schedule. This is legal and supported by the STEP trial data, but it's outside the approved dose range for the Ozempic product specifically.
Is 2.4 mg of semaglutide safe? Yes. The STEP trials enrolled nearly 5,000 patients at 2.4 mg weekly for up to 68 weeks with no unexpected safety signals. Side effects (nausea, vomiting, diarrhea) are more common at 2.4 mg than at lower doses but are generally manageable and transient.
How much more weight will I lose at 2.4 mg compared to 2.0 mg? Pooled trial data suggest 2.4 mg delivers about 1.5 percentage points more weight loss than 2.0 mg (roughly 3 to 4 pounds for a 220-pound patient). The difference is statistically significant but clinically modest for most people.
Why does Wegovy go to 2.4 mg but Ozempic stops at 2.0 mg? Wegovy was tested specifically for obesity in the STEP trials, which included a 2.4 mg arm. Ozempic was tested for diabetes in the SUSTAIN trials, which capped at 2.0 mg. The drugs are chemically identical, but the approved maximum doses differ because the trial programs were different.
What happens if I take 3.0 mg or higher? Doses above 2.4 mg haven't been studied in large trials. Small pharmacokinetic studies suggest semaglutide's half-life and receptor occupancy plateau above 2.4 mg, meaning higher doses likely don't increase efficacy but do increase side effects. No provider should prescribe above 2.4 mg outside a research protocol.
Do I have to titrate all the way to the maximum dose? No. Titration stops when you reach your weight-loss goal, experience intolerable side effects, or plateau despite dose increases. Many patients maintain long-term weight loss on 1.0 mg or 1.7 mg without ever reaching 2.0 mg or 2.4 mg.
Can I stay at 0.5 mg or 1.0 mg permanently? Yes, if that dose is effective for you. Some patients lose 10 to 15% of their body weight on 0.5 mg and maintain it indefinitely. The goal is the minimum effective dose, not the maximum approved dose.
How long does it take to titrate to the maximum dose? The standard Wegovy titration schedule reaches 2.4 mg at week 17 (four weeks each at 0.25 mg, 0.5 mg, 1.0 mg, and 1.7 mg, then 2.4 mg). Some providers extend the schedule to 20 or 24 weeks if side effects require slower escalation.
What if I plateau before reaching the maximum dose? A plateau at a submaximal dose can be dose-related (increasing the dose restarts weight loss) or behavioral/metabolic (increasing the dose doesn't help). A four-week trial at the next dose tier is a reasonable diagnostic test. If weight loss doesn't resume, focus on diet, activity, sleep, and stress rather than further dose increases.
Is compounded semaglutide dosed the same as Ozempic? Compounded semaglutide typically follows the same titration schedule as Wegovy (up to 2.4 mg weekly). The maximum dose is determined by your provider, not by an FDA-approved label, because compounded drugs are not FDA-approved products. Most compounding pharmacies supply concentrations that allow titration to 2.4 mg or higher.
Can I switch from Ozempic to Wegovy mid-treatment? Yes. If you're on Ozempic 2.0 mg and want to go to 2.4 mg, switching to Wegovy (if available and covered by insurance) is one option. The other option is continuing Ozempic off-label at 2.4 mg. The drugs are bioequivalent, so there's no washout period or re-titration needed.
Does insurance cover Ozempic at 2.4 mg for weight loss? Rarely. Most insurers cover Ozempic for diabetes at any approved dose (up to 2.0 mg) but deny coverage for weight loss regardless of dose. If you're using Ozempic off-label at 2.4 mg for weight loss, you'll likely pay out of pocket or use a compounded alternative.
What's the maximum dose of compounded semaglutide? Compounded semaglutide has no FDA-approved maximum because it's not an FDA-approved product. Most compounding pharmacies and providers follow the Wegovy schedule and cap at 2.4 mg weekly, but some protocols go to 3.0 mg or higher in research settings. Discuss with your provider.
How do I know if I need the maximum dose? You need the maximum dose if (1) you haven't reached your weight-loss goal, (2) you're still losing weight steadily at your current dose, (3) side effects are tolerable, and (4) increasing the dose is likely to help based on your response pattern. If you've plateaued or met your goal, you don't need the maximum dose.
Sources
- Frías JP et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3b trial. Lancet Diabetes & Endocrinology. 2021.
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
- Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
- Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
- Shi Q et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Diabetes, Obesity and Metabolism. 2022.
- Mahtta D et al. Trends in off-label prescribing of GLP-1 receptor agonists for weight management. JAMA Network Open. 2024.
- Fitch AK et al. Obesity medicine physician practices and perspectives on anti-obesity medications. Obesity Science & Practice. 2023.
- Jessen L et al. Glucagon-like peptide-1 receptor expression and agonist-induced downregulation in pancreatic beta cells. Endocrinology. 2012.
- Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN 6). New England Journal of Medicine. 2016.
- Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021.
- Rubino DM et al. Dose-response relationship of once-weekly semaglutide for the treatment of obesity. Obesity. 2023.
- Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
- Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8). Diabetes Care. 2019.
- Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →